Hong Kong Interior Design Firm Junee (JUNE) to Debut on the Nasdaq

HONG KONG, Apr 17, 2024 – (ACN Newswire) – Junee Limited, a well-known interior design company in Hong Kong, is pleased to announce that the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares at a price of $4.00 per share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on April 17, 2024 (Wednesday) under the ticker symbol “JUNE”, marking the company’s formal entry into the international capital market.

The company and its wholly-owned subsidiary, OPS Interior Design Consultant Limited (“OPS HK”), provides quality interior design, fit-out and maintenance services to both residential and commercial clients in the Hong Kong interior design market. The interior design service involves preliminary consulting services, conceptualizing clients’ design ideas with layout plans, and producing detailed design drawings. Fit-out work generally includes any activities making an interior space suitable for residential or commercial purposes.

OPS HK also provides a broad range of repair and maintenance services including routine home condition upkeep services. OPS HK won the Muse Design Award in 2020, and was the given Most Valuable Companies in HongKong Award 2020 by Mediazone.

For further information, please contact:
PEANUT MEDIA LIMITED
Direct Line: +86-755-61619798 x8210
Email: hswh.project@czgmcn.com

To acquire stake in Hangzhou Bizike, Phoenitron Holdings has eye on trillion-dollar e-commerce market

HONG KONG, Apr 17, 2024 – (ACN Newswire) – Beijing Tecsun Venus Technology Limited, an indirect wholly-owned subsidiary of Phoenitron Holdings Limited (8066.HK), has entered into a capital injection agreement with Hangzhou Bizike Intelligence Technology Company Limited stating its intention to subscribe registered capital of Hangzhou Bizike. When the transaction is completed, Beijing Tecsun Venus will hold 20% of the enlarged registered capital of Hangzhou Bizike. It will mark the Group’s formal entry into the trillion-dollar e-commerce market in the PRC, as well as enable it to expand its business and broaden its income sources.

The e-commerce market in the PRC has continued to grow over the past few years. That and the outbreak of the COVID-19 pandemic have driven consumers to shop online and in turn speeded up growth of the country’s e-commerce market, short video platforms and live stream commerce, encouraging businesses to pursue offline-to-online transformation, with success hinging on online marketing and sales through online KOL livestreaming. According to the market research company eMarketer, the retail e-commerce market of the PRC is expected to continue its growth and reach approximately RMB28.8 trillion in 2027, indicative of its huge development potential.

To Phoenitron, the thriving e-commerce market presents it with an important opportunity that agrees with its growth strategy and aim to diversity business. Thus, the decision to acquire Hangzhou Bizike, which is in e-commerce business, to support the Group in attaining strong growth of its business in the future and of its ability to generate revenue. Hangzhou Bizike’s main business is to market and sell merchandises via livestreaming, and it also provides short video marketing and creates IP for KOLs. It started preparations for its livestreaming business at the end of 2022, focusing on three main highest ROI (Return-on-Investment) product categories, namely womenswear, health products and beauty products, and started to record revenue in 2023. In just 10 months between June 2023 and March 2024, the transaction value generated through livestreaming exceeded RMB90 million, which was rather remarkable.

At present, Hangzhou Bizike is serving a famous Chinese women’s clothing brands, while also actively expanding its own brands and already has the brand LULU OCEAN registered. The brand specializes in women’s sportswear for all seasons, such as yoga wear. Hangzhou Bizike plans to use funds from the transaction on livestreaming of its own proprietary brands to promote product sales. What’s noteworthy is the company’s senior management is made up of former senior personnel of e-commerce platforms such as “Alibaba” and the leading short-video platform “douyin”. Bringing with them profound relevant experience, they have seen Hangzhou Bizike claim the top spot among livestreaming platforms on the Tencent Video streaming website.

The capital injection will allow Phoenitron to make Hangzhou Bizike’s livestreaming capability its own, foray into e-commerce business, build its own proprietary brand and capitalize on the growth momentum of the retail e-commerce market of the PRC. It is clear that the Group, via pursuing its active business development plan, is continuously exploring growth opportunities in different fields and such efforts will open more room for growth to it in the future.

The Group has recently announced its 2023 results, with revenue up by a notable 35.3% to approximately HK$79.1 million, and turning around from net loss last year to net profit of approximately HK$4.3 million. Such results plus the capital injection will prompt the market to re-evaluate Phoenitron’s worth, acting as an important catalyst to the Group’s market performance in the short term. In the long run, at its continuous effort to expand business and enhance profitability, the Group will have a solid foundation for future development and its long-term value will continue to show and catch eyes.

Microex Launches Web3.0 Financial Trading Solution – Pioneering Innovation in Financial Technology

NEW YORK, Apr 17, 2024 – (ACN Newswire) – Microex, a UAE-based financial technology company, today announced the launch of its web3.0 financial trading solution. This innovative platform marks a significant step forward in the financial technology industry.

Since its founding in August 2022, Microex has been dedicated to redefining and revolutionizing derivative trading. The company leverages the potential of Web3 technology to create a more accessible and efficient trading experience. Microex’s emphasis on mini-contracts, AI-driven smart trading bots, and advanced security features has positioned it as a major player in the global financial market.

Microex’s Distinctive Approach

Microex’s innovative mini-trading strategy differentiates it from traditional trading platforms. The core of its offering is the concept of mini-contracts, which allows users to act as mini-liquidity providers for exchanges. This novel approach disrupts existing markets and provides unmatched flexibility for both users and traders. Microex’s win-win strategy fosters a collaborative environment that benefits users, the platform, and market development agents.

Artificial Intelligence and High-Speed Hedging Algorithms

A standout feature of Microex is its AI-powered trading, which has consistently generated stable income for users over the past 19 months. Microex’s proprietary AI algorithms analyze market trends and execute hedging trades simultaneously across various platforms with precision and high speed. This offers users a secure and efficient trading experience in today’s fast-paced environment.

Unwavering Commitment to Security and Transparency

In an age where security is paramount, Microex prioritizes the safety of user funds. Its encrypted wallet features built-in anti-theft protection to safeguard against hacking attempts. Additionally, all transfers on Microex are completed on the blockchain, with the hash value of each transaction permanently stored in a public ledger. This immutable record guarantees the security, transparency, and trustworthiness of every transaction.

Future Development and Expansion:

Since its inception, Microex has transformed from a theoretical concept into a fully functional trading platform with profit-generating strategies. The company has recently obtained financial regulatory licenses in various regions to facilitate global market expansion. In January 2024, Microex was invited to Singapore for a venture capital roadshow by three prominent firms from the United States, Singapore, and Indonesia.

Microex’s achievements within a short timeframe can be attributed to the continuous dedication and innovation of its founder, Mr. Peng, and his team. Their unwavering commitment to excellence extends across all aspects of the business, from technical development and company management to market development.

Looking Ahead: Shaping the Future of Finance

In 2024, Microex will focus on developing decentralized applications (DApps) to streamline trading and portfolio management. The company is also developing a groundbreaking tool for recovering stolen cryptocurrencies. Additionally, Microex is exploring the integration of Web3 elements and non-fungible authority (NFA) tokens. These dynamic elements have the potential to revolutionize the financial landscape through smart contracts and community-driven decisions.

By 2025, Microex plans to develop and enhance more ecosystems, leveraging its vast trading data and user base to create even greater value. This positions Microex to shape the future of finance, redefine trading and investment methods, and usher in a new era of one-minute trading in the global financial market.

Social Links
X: https://twitter.com/MVG_MicroEx
Discord: https://medium.com/@microex.social
Instagram: https://www.instagram.com/mvg_microex/
Facebook: https://www.facebook.com/microventuregroup

Media contact
Brand: Microex
Contact: Media team
Website: https://www.microex.io/

SOURCE: Microex

CIRC Announces 2023 Annual Results

HONG KONG, Apr 17, 2024 – (ACN Newswire) – China Isotope & Radiation Corporation (“CIRC” or the “Company” , together with its subsidiaries, the “Group”; Stock Code: 1763.HK) announces the audited consolidated financial statements of the Group for the year ended 31 December 2023 (“2023” or the “Reporting Period”).

For the year ended 31 December 2023, the Group operated five business segments, namely pharmaceuticals, radioactive source products, irradiation, radiation therapy equipment and related services and other businesses. In 2023, the Group continued to intensify our market development efforts and achieved continued growth in economic efficiency. For the year of 2023, the Group recorded revenue of RMB6.635 billion, representing a year-on-year increase of 7.8%; gross profit was RMB3,482.2 million, gross margin was 52.5%; realized net profit of RMB776.1 million, representing a year-on-year increase of 2.8%, with net profit attributable to the parent company achieving RMB371.0 million.

Pharmaceutical segment: Magnificent development in existing industries and businesses with steady expansion of industry influence

In 2023, in respect of pharmaceutical segment, the Group provided a stable supply of radiopharmaceuticals to domestic medical institutions and strengthened the promotion of nuclear medicine diagnosis and treatment technology to clinical departments and other market development work, while continuously promoting development in existing industries and businesses. Through academic conferences and other means, the Group conducted scientific popularization for the general public and nuclear medicine clients on new products such as “therapeutic sodium iodine-131 capsule” and scientific radionuclide, enhancing its influence in the field of nuclear medicine. In December 2023, therapeutic sodium iodine-131 capsule manufactured by HTA Co., Ltd., a subsidiary of the Group, has successfully entered the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023) as a drug covered by the national medical insurance negotiations.

During the Reporting Period, the Group recorded RMB4,128.6 million in revenue from sales of pharmaceuticals, representing a year-on-year increase of 5.2%, accounting for 62.2% of the total revenue, recorded RMB1,682.8 million in revenue from imaging diagnostic and therapeutic radiopharmaceuticals, representing a year-on-year increase of 15.3%, and recorded RMB2,323.8 million in revenue from breath test.

Radioactive source products business: Successfully providing service for the Shenzhou XV manned spacecraft and remaining a high market share

In 2023, the supporting radioactive source developed by the Group for the Shenzhou XV manned spacecraft performed satisfactorily during the mission by ensuring accurate ignition command of the thrust reverser engine by the Y-altitude control device and safe and soft landing of the returning capsule, thereby guaranteeing the successful completion of Shenzhou XV manned mission. The technology of reusing retired radioactive source has made outstanding contributions in the field of applied research on circular economy, and won the First Prize of Sichuan Province Low Carbon Science and Technology Award. During the Reporting Period, a new type of domestically produced krypton [85kr] thickness gauge sources was officially launched into the market.

During the Reporting Period, the Group recorded RMB586.2 million in revenue from radioactive source products, representing a year-on-year increase of 0.9%. Gamma knife source and non-destructive testing radioactive source remained a stable and high market share, achieving growth in revenue, of which, gamma knife source realized operating revenue of RMB73 million and non-destructive testing radioactive source realized operating revenue of RMB89 million.

Irradiation business: Continuously innovating the mode of cooperation and sales revenue of new products reaching a record high

In 2023, the Company made innovation in the mode of cooperation and made deep-seated efforts to lay out its business in and explore EB curing industry, resulting in completion of technique and production line of EB plates, while arranging for EB color-coated plates and EB film so as to build EB curing industrial ecosystem. BINE High-Tech Co., Ltd., a subsidiary of the Group, successfully completed the after-sales maintenance for the 4 million curies BFT gamma irradiation equipment of Grand Ten Holdings in Malaysia, which is the first export project of BINE High-Tech Co., Ltd. and has maintained safe operation for 10 years without any incident.

During the Reporting Period, the Group actively explored the irradiation product market, with sales revenue of new irradiation products soaring to over RMB28.5 million, reaching a record high. The Group recorded RMB170.8 million in revenue from irradiation-related business.

Radiation therapy equipment and related services: Accelerating domestic manufacturing process of high-end radiotherapy equipment and the first product has successfully obtained approval

In 2023, the Group accelerated domestic manufacturing process of high-end radiotherapy equipment. On 28 September 2023, CNNC Accuray (Tianjin) Medical Technology Co., Ltd. (“CNNC Accuray”), a subsidiary of the Group, successfully obtained the medical device registration certificate issued by the National Medical Products Administration for its domestic high-end spiral tomotherapy system (TOMO C). This product has become the first domestic spiral tomotherapy product in the high-end medical field in China. The official mass production launch event and investor exchange meeting of TOMO C was held in Tianjin on 25 October.

In addition, CNHE-MDR, the outcome of the mobile digital medical X-ray photography system research and development project, was approved in June 2023 and obtained the medical device registration certificate. The Smart Cobalt-60-based Cone Beam Focused Stereotactic Therapy System project has completed the product type testing and entered the clinical trial stage smoothly. The SPECT/CT project has passed the general inspection and acceptance of the State Administration of Science, Technology and Industry for National Defence, with an acceptance rating of “excellent”.

During the Reporting Period, the Group recorded RMB933.7 million in revenue from nuclear medical equipment and related services, representing a year-on-year increase of 27.5%, and accounting for 14.1% of total revenue, making it the second largest source of revenue.

International business: Gradually deepening the global presence and making breakthroughs in a number of businesses

During the Reporting Period, the Group robustly explored the international market and exported breath test kits, radioimmunity kits, radiopharmaceuticals dispensing equipment, medical equipment and devices as well as other products to dozens of countries and regions such as Indonesia, Brazil, Peru, Colombia, Ecuador, India, Bangladesh, Singapore and Vietnam, realizing a total export revenue of RMB430 million. International business revenue from regular medical products maintained significant growth in 2023.

Marketing: Promoting brand building in an orderly manner and fully utilizing the value of the IAEA platform

During the Reporting Period, the Group deepened its brand building efforts. In May 2023, the Group successfully organized the “Sichuan Medical Isotopes and Radiopharmaceutical Industry Development Promotion Summit” in conjunction with eight departments in Sichuan Province. In September 2023, the Group contributed to and participated in the Conference on the High-quality Development of the Nuclear Technology Application Industry, the 2nd China-ASEAN Forum for Peaceful Use of Nuclear Technology, and etc. where the Group launched cooperation demonstration projects, signed business cooperation documents, and displayed nuclear medical equipment and digital exhibits for nuclear medicine. The Group participated in the Academic Annual Conference of the Nuclear Medicine Branch of the Chinese Medical Association in 2023 to launch the Radiant Intelligence 1.0 Intelligent Nuclear Medicine System, and co-hosted the 2nd International Forum on the Development of Nuclear Technology Application Industry in October 2023, fully demonstrating the CIRC’s leadership in nuclear technology application industry.

Furthermore, the Group has been actively leveraging the value of the IAEA Collaboration Center platform to enhance its international influence. In August 2023, the Group hosted the “International Training Course on Radiopharmaceuticals Preparation for the Asia-Pacific Region” in the name of the IAEA Collaboration Center for Radiopharmaceuticals and Radioactive Sources. The Group has persisted in reform of its marketing center to foster the synergistic, high-quality and safe development of its business in radiopharmaceuticals, radioactive sources and radioactive particles. In respect of the marketing of domestic nuclides, internal resources were coordinated and integrated for production, sales, distribution and services of domestic Lu-177 and Ge/Ga generators, laying the foundation for market development after reaching design capacity thereof in 2024.

Scientific research and innovation: Multiple projects conducting clinical trial and work related to intellectual properties gaining significant progress

The Group has always actively conducted research and development work on various types of imaging diagnosis and therapeutic pharmaceuticals to fill gaps in various fields of medical treatment and meet the medical needs of China. As of 31 December 2023, the Group had a number of imaging diagnosis and therapeutic radiopharmaceuticals under research and development. Among them, sodium fluorine injection has completed clinical trials and was submitted for new drug application; iodine-MIBG injection was in Phase III clinical trial; technetium sulfide colloidal injection, Ga-Dotatate injection, fluorine betazine injection, fluorine stamine injection, fluorine-L dopa injection and lutetium oxyoctreotide injection were approved for the clinical trial, and a variety of imaging diagnosis and therapeutic radiopharmaceuticals were in preclinical research and development stage.

During the Reporting Period, the Group yielded remarkable results in the work related to intellectual properties, with a total of 298 patents applied, 240 patent authorizations obtained, including 5 foreign design patent authorizations. As of 31 December 2023, the Group had 945 active licensed patents, among which there were 149 invention patents, sustaining and enhancing its technological strength. the Company had 11 registered trademarks, 38 registered copyrights, 1 national standard, 1 energy industry standard and 6 group standards issued, and 1 national standard, 1 agricultural industry standard, 4 nuclear industry standards and 12 group standards under preparation/to be released.

In terms of technological awards and honors, during the Reporting Period, the Group won 1 provincial and ministerial technology award, 4 social science and technology awards, 1 group-level science and technology award, and 3 awards in the CNNC Science and Innovation Competition.

Outlook

Looking ahead, CIRC will give full play to the unique advantages of nuclear medicine in the diagnosis and treatment of major diseases such as neurodegenerative diseases, cardiovascular and cerebrovascular diseases and malignant tumors, and provide quality products, services and integrated solutions to better protect people’s lives and health and facilitate the construction of “Healthy China”.

In 2024, the Company will firmly grasp the development opportunities, spare no effort, to maintain a good growth momentum, make every effort to drive the economic performance to a record high and practically improve the innovation and value creation capabilities, continuously strengthen the core functions and enhance the core competitiveness, and perform the three major roles of scientific and technological innovation, industry control, and safety support, in order to accomplish the planning objectives and tasks and accelerate the establishment of an internationally renowned isotope and radiation technology application products and services supply group.

About China Isotope & Radiation Corporation

China Isotope & Radiation Corporation (referred as “CIRC” or “the Company”) since its establishment in 1983, has been dedicated to exploring and developing nuclear technology applications. Boasting over 40 years of industry experience, the Company has emerged as a prominent leader in the domestic nuclear technology industry. The Group is primarily engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radio pharmaceuticals and radioactive source products for medical and industrial applications, the provision of irradiation service for sterilization purpose and engineering, procurement and construction (“EPC”) service for the design, manufacturing and installation of gamma ray irradiation facilities and the provision of nuclear medical equipment and services such as independent clinical laboratory services to hospitals and other medical institutions.

The nuclear medicine industry is an industry with immense potential, demanding threshold, and high returns. As a leader in China’s nuclear medicine industry, CIRC is the largest domestic manufacturer of imaging diagnostic and therapeutic radiopharmaceuticals, UBT diagnostic kits and test analyzers, as well as radioimmunity analysis kits. In field of radioactive source products, it is the only core enterprise in the field of radioactive source research and application that has industrialized and scaled research and production capabilities. In field of radiation, it is the third largest radiation processing service provider in China, and the only supplier in China that provides upstream production and downstream design and installation services for radiation equipment. And two of its subsidiaries have been approved by the Ministry of Ecology and Environment of the People’s Republic of China as two of the three EPC service providers authorized to engage in the design, manufacturing, and installation of radiation equipment.

Six Tips for building a website that really works for your business

SINGAPORE, Apr 17, 2024 – (ACN Newswire) – In today’s digitally connected world, consumers tend to expect every business to be fully searchable for product information, location, operating hours with an easily accessible website online. According to recent GoDaddy global research, 90% of small businesses surveyed said they felt that digitalization of their business was either very important or quite important to them.

With so much opportunity to share with your business with people in your local area and around the world, it is likely many businesses are considering how to build a stronger online presence this year.

GoDaddy shares six tips to help build a website to help a business be visible online and serve as a professional hub for your digital presence.

1. Consider the purpose of your website. When you know your business so well, it can be easy to get caught up in the design and functionality of what you know instead of what you would like consumers to know about your business. Take time to decide what is the purpose of your website and how do you want viewers to engage with it. It is a good idea to be very clear on the front page of your website on what your business offers. For example, a restaurant owner might want to show their location and menu images, while retailers might focus on showcasing their products for sale, and businesses selling experiences might consider videos and content as the best way to generate excitement before prompting a booking or inquiry.

2. Tell your story creatively. As a business owner, consider what might set you apart from everyone else in a similar business. Perhaps, it is the story behind why you do what you do. Videos, images, and blog content could be a great way for prospect customers to get to know your brand personality behind your business, as well as your story behind your business. This can lead to deeper connections with your target audiences which could positively impact the growth of your business and help to set you apart from the competition.

3. Be clear about your call-to-action. One way you could generate leads from a website is by having a clear call-to-action. The type of call-to-action you use could vary depending on the product or service your business offers. What would you like prospective and current customers to do on your website? Buy a product, learn more about your business by reading your blog, know where to find you on a map, see what your business does and how it might help the viewer solve a problem. It is important that your call-to-action be prominent on your website and encourages your customers to take a next step.

4. Start simply with lots of room for growth. It’s easy to get excited thinking about all the different website features and functions you could incorporate, but it’s important to pay close attention to what you really need to get started. A simple website is both easy and cost-effective to build, it can be easier for customers to navigate and come away with the information they were looking for. Starting simply can also allow you to find time to focus on updating with fresh quality content, fast loading speeds, and mobile optimization.

5. Focus on your target audience. Have a clear idea about who your target audience is and focus on delivering an exceptional online experience for them. There are many things about your target audience that could influence the design, function, and content on your website. Some key questions could include: How old are they? What activities do they like to do? How do they communicate? How do they consume content? The answers to all these questions can help you create a website that resonates with your target audience and can effectively communicate how your products or services solve their problems or fit with their lifestyle.

6. Choose the right website tools and hosting provider: Once you have determined the strategy for your website, the next step is to build it. The good news is that today there are tech tools that help to make it quick and easy to build and maintain a website without having a technical degree. GoDaddy Website Builder for example, offers templates, images, features text and other information to help you easily build a professional website for your business. You may choose to have your website hosted by the same provider where you have registered your domain, for a more integrated experience.Creating a home for your business on the internet can be a way to help you grow your business and stay engaged with your customers for many years to come. And now might be the best time to get started.

For more information on how GoDaddy can help your small business get started online: https://www.godaddy.com/en-ph

About GoDaddy

GoDaddy helps millions of entrepreneurs globally start, grow, and scale their businesses. People come to GoDaddy to name their idea, build a professional website, attract customers, sell their products and services, and accept payments online. GoDaddy’s easy-to-use tools help microbusiness owners manage everything in one place and its expert guides are available to provide assistance 24/7. To learn more about the company, visit www.godaddy.com.

Issued on behalf of GoDaddy.
For more information, contact:
Fekra Communications
info@fekracomms.com

Elevating Possibilities: The Countdown for WBS Dubai Begins!

DUBAI, Apr 16, 2024 – (ACN Newswire) – The World Blockchain Summit has established itself as a seminal series, bringing together a global cadre of blockchain enthusiasts, innovators, visionaries, thought leaders, and policymakers. This forum serves as a critical platform for deliberating on the integration and implications of blockchain technology across vital sectors, reflecting the global economy’s evolving digital landscape.

Amidst Dubai’s transition towards a digital-first economy, bolstered by strategic government initiatives and a burgeoning digital infrastructure, the city emerges as a global beacon for blockchain and web3 innovation. The inauguration of the Dubai AI & Web3 Campus by DIFC, coupled with the establishment of the Virtual Assets Regulatory Authority (VARA) in Dubai, underscores the region’s commitment to fostering a dynamic digital ecosystem, attracting investors and innovators worldwide.

The upcoming summit anticipates over 2,000 web3 decision-makers, 300+ investors, and more than 100 distinguished speakers. A highlight of the event is the regional finale of the Startup World Cup, orchestrated by the globally renowned venture capital firm, Pegasus Ventures. This competition offers startups a gateway to global recognition and a shot at securing US$1 million in funding at the global finals in San Francisco.

#WBSDubai will showcase a series of compelling keynote addresses, use-case presentations by leading blockchain experts, and thought-provoking panel discussions. The agenda will cover pivotal topics such as the role of Central Bank Digital Currencies (CBDCs), the potential of blockchain to enhance ESG impacts, and the importance of interoperability within the blockchain ecosystem and more.

Some of the notable speakers attending the event include:

· Pascal Gauthier, Chairman & CEO, Ledger

· Roham Gharegozlou, Co-founder and CEO, Dapper Labs

· George Gvazava, Chief Crypto Officer, Bank of Georgia

· Miriam Kiwan, Vice President of MEA, the issuer of leading regulated stablecoin, USDC., Circle

· Yosuke Yoshida, Co-CEO of EMURGO Middle East & Africa CEO of EMURGO Kepple Ventures, EMURGO

· Bandar Altunisi, Head of Development for Binance in Saudi Arabia Head of Institutional Relationships for Binance Dubai (FZE), Binance

· Stefan Kimmel, CEO, M2

· Richard Muirhead, Managing Partner, Fabric Ventures

Sharing their enthusiasm about the event, George Gvazava, Chief Crypto Officer, Bank of Georgia said,” In the realm of innovation, the World Blockchain Summit serves not only as a gathering of minds but as a crucible, where ideas are forged into the connections, use-cases and technologies of tomorrow.”

“As Dubai spearheads the UAE’s digital transformation, blockchain technology plays a central role. Trescon is at the nexus, linking pioneering entrepreneurs with elite global investors. The World Blockchain Summit stands as the definitive forum for revealing the forefront of blockchain innovation and insights,” states Sharath Ravi, CMO, Trescon.

Hurry, registration for the World Blockchain Summit in Dubai is still available! Reserve your spot now to be part of one of the year’s most anticipated blockchain and cryptocurrency gatherings. Act fast to seize this exclusive chance to participate and secure your tickets and sponsorship today!!

The 29th edition of the World Blockchain Summit is supported by:

Strategic Partners – DIFC Innovation Hub , Dubai AI & Web3 Campus
Co-Host – Sun Minimeal
After Party Sponsor – Floxypay
Gold Sponsors – Cardano Foundation , Medifakt, Crypto2Cash, Anbruggen, Bitflex
Silver Sponsors- Kreation, Coingames, Reat Capital , ACM Finance , Website AI
Lanyard Sponsor- M2
Badge Sponsor – Ledn
Lunch Sponsor – Payper
Bronze Sponsor- BitGo, M2 , Block Convey, Genesis Digital Assets , Hedge , Golfin
Pitch Partners – Reat Capital , soukcola , MeAI , Zherpa , FidesInnova Labs
Exhibitors- DSQ Solutions , Reltime, Qoneqt , C# Corner , Islamic Dinar
Official Accommodation Partner- HotelPlanner
Ecosystem Partner – Entrepreneur Media
Business Broadcast Partner – CNBC Arabia
Official Newspaper Partner- The Fintech Times
Official Digital PR Distribution Partner – ZEX PR Wire

ABM Partner- Demandify

Association Partners- Crypto and Blockchain Association, Blockchain Council, Asia Web3 Alliance Japan, European Blockchain Association

Prime Media Partner- Demandteq

Community Partner – Hyperledger Foundation

About World Blockchain Summit (WBS)

World Blockchain Summit (WBS) is an event by Trescon that supports the growth of the blockchain, crypto and Web3 ecosystem globally.

WBS is the world’s longest-running blockchain, crypto, and web 3-focused summit series. Since our inception in 2017, we have hosted more than 20 editions in 11 countries as we strived to create the ultimate networking and deal flow platform for the Web3 ecosystem. Each edition brings together global leaders and emerging startups in the space, including investors, developers, IT leaders, entrepreneurs, government authorities, and others.

To book your tickets, visit https://tinyurl.com/3svvkndr.

Contact:
Shadi Dawi
Director, Public Relations & Partnerships – MENA, Trescon
shadi@tresconglobal.com
+971 55 498 4989

InnoEX, Spring Electronics Fair boost tech hub status

2nd InnoEX, 20th HKTDC Hong Kong Electronics Fair (Spring Edition) drew some 88,000 buyers from 139 countries and regions
Apart from local visitors, the fairs welcomed buyers mainly from Mainland China, India, Japan, Korea and the United States
31% of the local exhibitor respondents consider AI as the strongest I&T field in Hong Kong, followed by Fintech (27%)
Product categories with strong growth potential seen as smart home or smart living products and solutions (23%), electronic or electrical accessories (20%) and home appliances (16%)

HONG KONG, Apr 16, 2024 – (ACN Newswire) – The second edition of InnoEX, co-organised by the Innovation, Technology and Industry Bureau of the Hong Kong SAR Government and the Hong Kong Trade Development Council (HKTDC), along with the 20th HKTDC Hong Kong Electronics Fair (Spring Edition), concluded today following four resoundingly successful days. This year’s fairs attracted some 88,000 buyers from 139 countries and regions, mainly from mainland China, India, Japan, Korea and the United States, highlighting Hong Kong’s advantages in its pursuit to become an international innovation and technology (I&T) centre.

Sophia Chong, HKTDC Deputy Executive Director, said: “InnoEX and the Electronics Fair, as signature events of the Business of Innovation and Technology Week (BITWeek), along with a series of fascinating events, synergistically fostered international technological innovation in Hong Kong, propelling the region towards unparalleled economic and social development. The findings of the survey conducted during the events underscore the prevailing optimism among exhibitors and buyers regarding promising business prospects. Capitalising on Hong Kong’s esteemed position as an international trade centre, the HKTDC is committed to supporting companies in expanding their market reach for innovative products, fortifying the I&T ecosystem, and augmenting local I&T capabilities.”

At InnoEX the Smart Hong Kong Pavilion set up by the Office of the Government Chief Information Officer (OGCIO) showcased over 100 technology solutions closely related to people’s daily lives through interactive experience and live demonstrations. The Innovation and Technology Commission (ITC) also presented remarkable AI and robotics technology achievements by 16 research centres under InnoHK. Numerous Hong Kong pavilions and tech companies introduced innovative projects that received positive feedback from industry professionals. The exhibition also featured 20 pavilions from 16 provinces and cities in Mainland China, along with the So French So Innovative pavilion and the India and Canada pavilions, showcasing cutting-edge technologies such as aerospace and satellite technology, chips, data analysis, AI and robotics that can be adopted across various industries. The pavilions attracted many buyers interested in further understanding products and solutions, and engaging in business negotiations.

PTF AreaTech Company Ltd, a Hong Kong start-up exhibiting at InnoEX, is working with a state-owned enterprise to promote application of BeiDou satellite technology in Hong Kong and ASEAN countries. Jonathan Maang, Chief Technology Officer of the company, said: “On the first day of the exhibition, we were visited by representatives from several Hong Kong government departments who provided valuable advice to help us optimise our technological solutions. In just a day and a half we received nearly 120 guests, including potential buyers from Japan and ASEAN. The exhibition has opened the international market for us and presented us with numerous business opportunities. We look forward to showcasing even more of our application solutions at next year’s exhibition.”

InnoEX attracted many heavyweight buyers. Don Tsang, Senior Business Director, Digital Technology Business, Ant Group, said: “The scale and international scope of InnoEX is truly impressive. The exhibition enables us to connect with exhibitors hailing from Southeast Asia, Europe and the United States. The innovations showcased have the potential for wide-ranging applications across diverse industries. What particularly captured my attention were the exhibitors from Shenzhen. Their products have already reached a high level of maturity and have successfully attained dominant market leadership. I look forward to attending InnoEX again next year!”

Hong Kong exhibitor Greentek participated in the Spring Electronics Fair for the 20th year. Ken Cheung, Regional Sales Manager of the company, stated: “Around 50 buyers, mainly from Europe and the US, showed interest in our products including TV components and smart storage boxes, and we have already received on-site orders totalling approximately US$200,000. We will definitely participate at the fair again next year.” Additionally, Korean juicer company Hurom also leveraged the fair to connect with buyers from emerging markets such as India, Malaysia, Russia and Turkey with the hope of expanding into more new markets.

Nico Broder, CEO of Spanish company Atlantis Internacional SL, was sourcing smartwatches, smartphones and mobile accessories at the Spring Electronics Fair. He said: “We are expanding our product range, and have already found new suppliers at the exhibition. We expect to purchase products valued between US$2 million and US$4 million.”

ASEAN Roundtable fosters cooperation; Nobel laureates share insights

Highlighted InnoEX events included the ASEAN Roundtable, which brought together officials from ASEAN countries, Mainland China and representatives from research institutions who discussed smart-city strategies and needs. The discussions covered topics such as promoting digitalisation, enhancing citizens’ digital skills, supporting start-up development, practicing sustainable development and a people-centric approach, and strengthening internet coverage and security. Exhibitors also introduced I&T solutions. Representatives from ASEAN, Mainland China and Hong Kong SAR Government officials had in-depth exchanges at the meetings and appreciated the discussions, believing they contributed to promoting government-to-government (G2G) and government-to-business (G2B) cooperation.

Dr Alias Bin Rameli, Director General of Town and Country Planning, Ministry of Local Government Development, Malaysia, attended the Roundtable discussion and led a delegation of representatives from Malaysia’s 16 states and federal territories to visit InnoEX. He stated: “We came across many products and technologies with great potential, such as solutions for water management and wastewater treatment. Malaysia’s smart city development initiative holds the potential to unlock over a thousand business collaboration opportunities. We leveraged this exhibition to establish valuable partnerships and explore deeper avenues for cooperation. We will continue to seek suitable technological solutions to advance our development goals.”

The Hong Kong Alumni Association of Beijing Universities set up a pavilion and organised the inaugural Hong Kong World Youth Science Conference during InnoEX, inviting Nobel laureates, Turing Award winners, I&T professionals and renowned scientists to share insights. The conference attracted enthusiastic participation and engagement from professionals across various sectors.

Recognising the crucial role of young talent in promoting I&T ecosystem development, this year’s InnoEX and Spring Electronics Fair introduced Exhibitors Meet Talents. This initiative, aimed at helping exhibitors attract talent, drew job seekers to explore employment opportunities and engage in discussions with prospective employers.

AI considered most promising field in local I&T industry

Independent surveys commissioned by the HKTDC at the fairs, with over 340 respondents from InnoEX and 670 from the Electronics Fair, made several key findings:

InnoEX

31% of the local exhibitor respondents identified AI as the strongest and most advantageous I&T area in Hong Kong, followed by Fintech (27%).
37% of respondents believed the market growth potential of I&T is the greatest in the Guangdong-Hong Kong-Macao Greater Bay Area cities in Mainland China, followed by other mainland cities such as Beijing, Shanghai and Chengdu (36%), ASEAN countries (27%) and Hong Kong (26%).
Local exhibitor respondents believed Hong Kong start-ups have the greatest advantage and potential in the field of AI research (24%), followed by information and communications technology (21%).

Spring Electronics Fair

Exhibitors were optimistic with 64% of respondents anticipating an increase in overall sales in the next one to two years.
Participants identified smart home and smart living products and solutions (23%), electronic and electrical accessories (20%) and home appliances (16%) as the electronics product categories with the highest growth potential in major markets this year.
Respondents believe that in the next two years, potential is highest for extended reality (XR) in audiovisual entertainment uses, as well as mobile and online games (both at 26%).

The exhibitions adopt the HKTDC’s EXHIBITION+ model, merging online and offline elements. Exhibitors and buyers can continue to network through the Click2Match smart business-matching platform until 23 April (Tuesday).

Photos Download: https://bit.ly/442qeaB

The second edition of InnoEX, co-organised by the Innovation, Technology and Industry Bureau of the Hong Kong SAR Government and HKTDC, together with the 20th HKTDC Hong Kong Electronics Fair (Spring Edition), concluded today, attracting some 88,000 buyers from 139 countries and regions

The Smart Hong Kong Pavilion set up by the Office of the Government Chief Information Officer (OGCIO) showcased over 100 technology solutions closely related to people’s daily lives through interactive experience and live demonstrations. These solutions were very well-received by attendees

The Shenzhen pavilion showcased a range of cutting-edge I&T solutions, featuring advancements in drones, robotics and ultra-fast electric vehicle charging technologies, which garnered keen interest from numerous buyers

AUBO (Shandong) Robotics Technology Co., Ltd showcased collaborative robots that can be applied in various scenarios, drawing keen interest from numerous buyers

ASEAN Roundtable brought together officials from ASEAN, Mainland China and the Hong Kong SAR Government to discuss strategies and needs for developing smart cities

The Hong Kong/Shanghai Data Co-operation Forum – Data Flow: Ecology x Compliance x Scenario invited industry leaders from Shanghai and Hong Kong to discuss topics including the Shanghai-Hong Kong data ecosystem in the context of the action plan of the National Data Bureau for the next three years, the value of data assets, and digital business

The Hong Kong World Youth Science Conference invited numerous high-profile guests, including several Nobel Prize and Turing Award winners. Here Edward I. Moser, the 2014 Nobel laureate in Physiology or Medicine, delivers his speech

The So French So Innovative pavilion held a focusing on industry development, smart mobility, green technology and building technology. The seminar explored how innovative technologies from France can drive sustainable development worldwide

The Tech Trends Symposium at Electronics Fair discussed the Future of Spatial Computing & Generative AI. Industry experts analysed the latest developments in related technologies and equipment, as well as real-life application cases

Websites
InnoEX: innoex.hktdc.com/en
Hong Kong Electronics Fair (Spring Edition): hkelectronicsfairse.hktdc.com/en

Media enquiries

Yuan Tung Financial Relations:

Anson Wong	Tel: (852) 3428 3413	Email: awong@yuantung.com.hk
Salina Cheng	Tel: (852) 3428 2362	Email: salcheng@yuantung.com.hk
Hing-fung Wong	Tel: (852) 3428 3122	Email: hfwong@yuantung.com.hk

HKTDC’s Communications & Public Affairs Department:

Clayton Lauw	Tel: (852) 2584 4472	Email: clayton.y.lauw@hktdc.org
Phyllis Tsang	Tel: (852) 2584 4288	Email: phyllis.km.tsang@hktdc.org

HKTDC Media Room: http://mediaroom.hktdc.com

To view press releases in Chinese, please visit http://mediaroom.hktdc.com/tc

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn

CleverTap bags ten prestigious awards at the 2024 Stevie Awards

Mountain View, Calif, & Mumbai, India, Apr 16, 2024 – (ACN Newswire) – CleverTap, the all-in-one engagement platform, bags ten prestigious awards at the 2024 Stevie Awards, the world’s premier business awards platform. The company received global recognition winning several awards along with its customers, for various innovative campaigns with Ooredoo Group, SonyLIV, Decathlon, and The Times of India. The company also won several awards for technology and product innovation and for building a strategic partner approach to customer service.

The Stevie Awards are widely considered to be the world’s premier awards for achievement in business, conferring recognition for achievement in programs for 22 years. CleverTap wins big at the Global 18th Annual Sales and Customer Service awards held at the Bellagio, Las Vegas, and 11th Annual Stevie Asia-Pacific Awards for excellence in technology development, building solutions for businesses, and creating a holistic approach to customer service from onboarding to support to success.

The Stevie Awards for Sales & Customer Service are open to all organizations worldwide, and recognize the achievements of sales, customer service, and professionals.

Stevie recognized organizations across the globe and this year witnessed more than 2,300 nominations for Stevie Sales & Customer Service Awards and over 1,000 nominations from organizations across the Asia-Pacific region in categories such as Excellence in Innovation in Products & Services, Innovative Management, and Innovation in Corporate Websites, among many others.

The awards that CleverTap won this year include:

CleverTap winning together with customers:

Ooredoo and CleverTap win gold for innovation in business information apps, for revolutionizing app engagement with a holistic approach to customer engagement
The Times of India and CleverTap win gold for innovation in general information apps, for pioneering AI-powered personalization behind the news headlines
SonyLIV and CleverTap win bronze for innovation in entertainment apps, for revolutionizing real-time sports entertainment for the 19th asian games campaign
Decathlon and CleverTap win bronze for innovation in shopping or e-commerce apps, for revolutionizing retail by crafting advanced personalized shopping experiences

Product Innovation Awards:

CleverTap bags gold for innovation in business-to-business products & services as the all-in-one pioneer in customer engagement and retention solutions for businesses
CleverTap wins silver for its achievement in product innovation category, for revolutionizing customer engagement with innovative solutions
CleverTap bags silver for innovation in technology development

Customer Service Awards:

CleverTap wins gold for being a strategic partner in growth through customer-centric service innovation for its customers and gets recognised for innovation in customer service management, planning & practice category
CleverTap bags silver in best customer engagement initiative category for building a holistic approach to customer engagement, from onboarding, support to success
CleverTap wins silver for revolutionizing customer experience becoming a strategic partner in the customer journey in achievement in customer experience category

Gold, Silver and Bronze Stevie Award winners were determined by a rigorous process of evaluation with the average scores of more than 100 distinguished industry practitioners in February and March.

“The 11th edition of the Asia-Pacific Stevie Awards attracted many remarkable nominations,” said Stevie Awards president Maggie Miller. “The organizations that won this year have demonstrated that they are committed to being innovative, and we applaud them for their perseverance and creativity. We look forward to celebrating many of this year’s winners during our awards banquet on 24 May.”

“We are honored to have bagged multiple awards at the 2024 Stevie Awards. Stevie 2024 is special for us as we have received multiple recognitions across various domains, including our products, customer service, and collaborations with customers while innovating solutions for each industry. It is a testament to our relentless pursuit of helping our customers achieve their business goals by maximizing customer lifetime value,” said Sidharth Malik, CEO, CleverTap. He further added, “This recognition underscores the importance of being a strategic partner to customers and understanding each customer’s unique priorities and delivering measurable outcomes. These award wins are as much for our fellow CTzens as they are for our customers. It is the dedication and efforts of teams across functions that has helped us do the award-winning work. The Stevie wins will further motivate us to continue innovating and exceeding expectations.”

About CleverTap

CleverTap is the all-in-one engagement platform that helps brands unlock limitless customer lifetime value by helping them create personalised experiences to retain their most valuable customers. The platform empowers businesses to orchestrate experiences for individuals across their lifecycles and design personalised journeys that span a lifetime. It offers analytics encompassing every aspect of the lifecycle, enabling businesses to measure and optimise each experience in real-time. Its unique AI capability is insightful, empathetic, and prescriptive, facilitating smarter and faster decisions. The all-in-one platform unifies experiences from every touchpoint, paving the way for a new era of customer engagement.

The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering both speed and economies of scale.

CleverTap is trusted by 2000 customers, including Electronic Arts, TiltingPoint, Gamebasics, Big Fish, MobilityWare, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco.

Backed by leading investors such as Peak XV Partners, Tiger Global, Accel, CDPQ, and 360 One, the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, and Jakarta.

For more information, visit clevertap.com or follow us on:
LinkedIn: https://www.linkedin.com/company/clevertap/
X: https://twitter.com/CleverTap

About the Stevie® Awards

Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service, the new Stevie Awards for Technology Excellence, and the Stevie Awards for Women in Business,. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com .

Sponsors and partners of the 2024 Asia-Pacific Stevie Awards include Adobo Magazine and PR Newswire Asia.

Forward-Looking Statements

Some of the statements in this press release may represent CleverTap’s belief in connection with future events. They may be forward-looking statements or future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being different from the results anticipated by the statements mentioned in the press release.

Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, the impact of a pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, regarding the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.

For more information:
SONY SHETTY
Director, Public Relations, CleverTap
+91 9820900036
sony@clevertap.com

IPSHITA BALU
Consultant
Archetype
+91 9590111798
ipshita.balu@archetype.co

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

HONG KONG, Apr 16, 2024 – (ACN Newswire) – SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, is pleased to announce that the preclinical works of SM17, a humanised IgG4 monoclonal antibody against IL-17RB, is published on Allergy, an official journal of the European Academy of Allergy and Clinical Immunology (EAACI), on 9 April, 2024. This article compared the efficacy of SM17 in alleviating symptoms of atopic dermatitis (AD) with that of FDA approved JAK1 inhibitor in a preclinical setting (animal data), and confirmed that animals treated with SM17 exhibited a similar, if not better, therapeutic responses than those treated with the FDA approved JAK1 inhibitor. The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.

SM17 is a novel, first-in-class (FIC) IgG4 monoclonal antibody targeting IL-17RB (also known as interleukin 25 (IL-25) receptor) with the potential for treating atopic dermatitis, asthma, idiopathic pulmonary fibrosis and other immunological and autoimmune disorders. In Phase I clinical trials (NCT05332834) performed in the US, SM17 showed a good safety profile with no drug-related serious adverse event (SAE) reported, demonstrating superiority over other JAK1 inhibitor in safety and tolerability.

AD is a chronic inflammatory skin disease that is characterised by intense itching and recurrent blisters. AD patients are known to have low treatment satisfaction and there exists a huge unmet medical need for a safer and more efficacious treatment option. AD is driven by Th2 immunity where IL-25 is one of the key mediators that drives the whole cascade of events leading to ILC2 and Th2 cell activation, resulting in inflammatory skin swelling, itching, skin irritation and other symptoms characteristic of AD. The Company has developed SM17, a IgG4 monoclonal antibody, that targets a co-receptor for IL-25 (also known as IL-17RB), with the purpose of blocking the early (upstream) events induced by IL-25, in the hope of achieving a differentiating treatment modality for AD that is fast-acting, efficacious and safe. Current products in the market are either fast-acting and efficacious but with safety concerns (JAK1 inhibitor) or relatively slow to respond and less efficacious yet with better safety profile (anti-IL-4Ra antibody). The Allergy article and the results of the US Phase I study scientifically validated the favourable efficacies and good safety profile of SM17 for treating AD.

In addition to AD, SM17 is found to exhibit therapeutic potentials for treating asthma, idiopathic pulmonary fibrosis and other type 2 immunological disorders. Studies to explore the therapeutic potential of these indications are on-going.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that: “SinoMab focuses on the development of innovative products through scientific excellence, with the goal of identifying differentiating products that address immunological diseases of unmet medical needs. We are pleased that evidence demonstrating the advantageous therapeutic potential of SM17 for treating AD is scientifically confirmed and endorsed by being published on the renowned peer-reviewed journal Allergy. The global market size for AD is estimated to reach US 27.68 billion by 2030, according to a new report by Grand View Research, Inc. Currently, the two most prescribed products for AD are the FDA approved anti-IL-4Ra antibody and JAK1 inhibitor. Studies indicated that JAK1 inhibitor is comparatively faster acting and achieving better response than anti-IL-4Ra antibody. However, JAK1 inhibitor has a black box warning, making anti-IL-4Ra antibody more receptive in the medical community due to its better safety profile. Our results indicated that SM17 appeared to have the best of both worlds: SM17 is comparable to (if not better than) JAK1 inhibitor in “time to response (anti-itching)”(unpublished data), and “therapeutic efficacies” in a preclinical model, as illustrated in the Allergy article, and comparable to (if not better than) anti-IL-4Ra antibody in tolerability and safety as demonstrated in our US Phase I study. SM17 is an innovative product with differentiating therapeutic and safety properties that compete favourably with existing treatment options. The preclinical results will be confirmed in human in a proof of concept clinical trial in AD patients that was initiated in April 2024.”

About SinoMab BioScience Limited

SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company’s flagship product SM03 (Suciraslimab) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer’s disease, systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), asthma, and other diseases with major unmet clinical needs.

About Allergy

Allergy, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI), aims to advance, impact and communicate all aspects of the discipline of Allergy/Immunology including educational, basic, translational and clinical research and maintain contact between basic and clinical Allergy/Immunology.

Allergy is an international journal with contributors and readers from all countries. Allergy publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors and correspondences.

For more information about SM17, please read the published article on Allergy.

Link http://doi.org/10.1111/all.16120

This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:

Financial PR (HK) Limited

Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Amy Yang
Email:	sinomab@financialpr.hk
Tel:	(852) 2610 0846	Fax: (852) 2610 0842

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

NEW YORK, Apr 16, 2024 – (ACN Newswire) – A new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company’s groundbreaking approach to peripheral nervous system (PNS) disorders, has been published by Benzinga. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.

The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related disorders. By targeting the root causes associated with the PNS, rather than just managing symptoms, Autonomix Medical’s technology offers a novel solution that combines both detection and ablation of problematic nerves in a single procedure. This approach, likened to a “GPS” for nerve treatment, allows for precise identification and treatment of the nerves involved, enhancing the accuracy and effectiveness of procedures.

In a notable application, the company is focusing its efforts on managing pancreatic cancer pain — a condition notoriously difficult to treat due to its proximity to critical nerves. The technology’s high sensitivity in detecting neural signals—up to 3,000 times greater than existing technologies — promises not only to improve outcomes in pain management but also to significantly reduce the need for opioids, addressing a major public health challenge.

This exposure in Benzinga underscores the potential of Autonomix Medical’s technology to transform the field of electrophysiology and pain management, potentially tapping into a market exceeding $100 billion. As the company progresses with its clinical trials, the successful implementation of its technology could revolutionize treatment approaches for a wide range of diseases, offering hope to millions of patients worldwide.

To read the full article, click here.

More Pancreatic Cancer News:

Candel Therapeutics, Inc. ((Nasdaq: CADL) announced that the FDA has granted Orphan Drug Designation to their advanced biological immunotherapy, CAN-2409, for treating pancreatic cancer, following promising phase 2 clinical trial results that more than doubled median overall survival when added to standard care.
RenovoRx, Inc. (Nasdaq: RNXT) announced an $11.1 million private placement, extending their financial runway into 2026, which will support the continuation and completion of their pivotal Phase III TIGeR-PaC clinical trial for pancreatic cancer. This funding also facilitates the expansion of their Trans-Arterial Micro-Perfusion (TAMP) clinical development pipeline into additional cancer indications.

Note: The details provided in this press release are based on information featured in the Benzinga article and do not constitute forward-looking statements.

For more information, contact:
Plato Data Intelligence
144 E44th St
New York NY 10017
PlatoAiStream.com
Zephyr@platodata.io